4D Molecular Therapeutics (FDMT) Revenue & Revenue Breakdown
4D Molecular Therapeutics Revenue Highlights
Main Segment (Y)
Collaboration And License Revenue
Main Geography (Y)
UNITED STATES
4D Molecular Therapeutics Revenue by Period
4D Molecular Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | - | -100.00% |
| 2022-12-31 | $3.13M | -82.65% |
| 2021-12-31 | $18.04M | 32.52% |
| 2020-12-31 | $13.61M | 94.85% |
| 2019-12-31 | $6.99M | -50.56% |
| 2018-12-31 | $14.13M | 144.04% |
| 2017-12-31 | $5.79M | - |
4D Molecular Therapeutics generated - in revenue during NA 2023, up -100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
4D Molecular Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-09-30 | - | -100.00% |
| 2024-06-30 | $5.00K | -82.14% |
| 2024-03-31 | $28.00K | -247.37% |
| 2023-12-31 | $-19.00K | -100.09% |
| 2023-09-30 | $20.20M | 8353.56% |
| 2023-06-30 | $239.00K | -19.80% |
| 2023-03-31 | $298.00K | -76.10% |
| 2022-12-31 | $1.25M | 149.40% |
| 2022-09-30 | $500.00K | 208.64% |
| 2022-06-30 | $162.00K | -86.71% |
| 2022-03-31 | $1.22M | 1225.00% |
| 2021-12-31 | $92.00K | -93.27% |
| 2021-09-30 | $1.37M | -90.63% |
| 2021-06-30 | $14.58M | 629.00% |
| 2021-03-31 | $2.00M | -304.71% |
| 2020-12-31 | $-977.00K | -113.17% |
| 2020-09-30 | $7.42M | 104.27% |
| 2020-06-30 | $3.63M | 2.77% |
| 2020-03-31 | $3.54M | 74.14% |
| 2019-12-31 | $2.03M | 275.93% |
| 2019-09-30 | $540.00K | -75.54% |
| 2019-06-30 | $2.21M | - |
| 2019-03-31 | $2.21M | -51.26% |
| 2018-12-31 | $4.53M | - |
| 2018-09-30 | $4.53M | 78.75% |
| 2018-06-30 | $2.53M | - |
| 2018-03-31 | $2.53M | - |
4D Molecular Therapeutics generated - in revenue during Q3 2024, up -100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
4D Molecular Therapeutics Revenue Breakdown
4D Molecular Therapeutics Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 |
|---|---|---|---|---|
| Collaboration And License Revenue | $20.01M | $3.13M | $18.04M | $13.61M |
4D Molecular Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 23: Collaboration And License Revenue (100.00%).
Quarterly Revenue by Product
| Product/Service | Sep 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Collaboration And License Revenue | $3.00K | $28.00K | - | $20.01M | $239.00K | $298.00K | $1.25M | $500.00K | $162.00K | $1.22M | $12.00K | $64.00K | $14.58M | $2.00M |
4D Molecular Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Collaboration And License Revenue (100.00%).
4D Molecular Therapeutics Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 23 | Dec 22 | Dec 21 | Dec 20 |
|---|---|---|---|---|
| NETHERLANDS | $567.00K | $3.09M | $736.00K | $742.00K |
| UNITED STATES | $20.16M | $35.00K | $121.00K | $-27.00K |
| SWITZERLAND | - | - | $17.18M | $12.90M |
| AUSTRALIA | - | - | - | - |
4D Molecular Therapeutics's latest annual revenue breakdown by geography, as of Dec 23: UNITED STATES (97.26%), and NETHERLANDS (2.74%).
Quarterly Revenue by Country
| Country | Sep 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| UNITED STATES | $3.00K | $28.00K | - | $20.16M | $9.00K | $3.00K | $2.00K | $3.00K | $2.00K | $28.00K | $89.00K | $12.00K | $16.00K | $3.00K |
| NETHERLANDS | - | - | $1.00K | $41.00K | $230.00K | $295.00K | $1.25M | $497.00K | $160.00K | $1.19M | $12.00K | $64.00K | $267.00K | $392.00K |
| SWITZERLAND | - | - | - | - | - | - | - | - | - | - | $-9.00K | $1.29M | $14.30M | $1.60M |
4D Molecular Therapeutics's latest quarterly revenue breakdown by geography, as of Sep 24: UNITED STATES (100.00%).
4D Molecular Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| RVMD | Revolution Medicines, Inc. Warrant | $11.58M | - |
| STOK | Stoke Therapeutics | $8.78M | $4.89M |
| KRON | Kronos Bio | $6.29M | $2.37M |
| IPSC | Century Therapeutics | $2.23M | $791.00K |
| LYRA | Lyra Therapeutics | $1.56M | $195.00K |
| FIXX | Q32 Bio | $1.16M | - |
| BCEL | Atreca | $770.00K | $80.00K |
| CGEM | Cullinan Oncology | - | - |
| BDTX | Black Diamond Therapeutics | - | - |
| CCCC | C4 Therapeutics | - | - |
| GOSS | Gossamer Bio | - | $9.48M |
| REPL | Replimune Group | - | - |
| PASG | Passage Bio | - | - |
| BMEA | Biomea Fusion | - | - |
| MLYS | Mineralys Therapeutics | - | - |
| NVCT | Nuvectis Pharma | - | - |
| AKRO | Akero Therapeutics | - | - |
| FDMT | 4D Molecular Therapeutics | - | - |
| EWTX | Edgewise Therapeutics | - | - |